Helicobacter pylori: ¿cómo mejorar las terapias de erradicación?

Autores/as

  • Jorge Alfredo Morcillo-Muñoz Universidad Nacional de Colombia http://orcid.org/0000-0002-9912-6433
  • William Alberto Regino-Otero Universidad Nacional de Colombia
  • Martín Alonso Gómez Zuleta Universidad Nacional de Colombia

DOI:

https://doi.org/10.22516/25007440.314

Palabras clave:

Helicobacter, resistencia, inhibidores de la bomba de protones, antibióticos

Resumen

Desde el descubrimiento de Helicobacter pylori, la erradicación del mismo ha sido un reto constante y el tratamiento ideal todavía no está disponible. La creciente resistencia del microorganismo a los antibióticos más frecuentemente utilizados es la circunstancia que más ha impactado en la eficacia de los diferentes esquemas. El objetivo del presente trabajo es revisar los aspectos generales de la infección por H. pylori, los aspectos básicos de los componentes de las terapias de erradicación, la nomenclatura de los distintos tratamientos, las características generales de los antibióticos y, finalmente, los tratamientos recomendados con base en las publicaciones recientes más importantes.

 

Descargas

Los datos de descargas todavía no están disponibles.

Lenguajes:

es

Biografía del autor/a

Jorge Alfredo Morcillo-Muñoz, Universidad Nacional de Colombia

Médico cirujano de la Universidad Nacional de Colombia. Bogotá

William Alberto Regino-Otero, Universidad Nacional de Colombia

Profesor de medicina, Unidad de Gastroenterología, Universidad Nacional de Colombia. Hospital Universitario Nacional, Gastroenterólogo, Clínica Fundadores, Bogotá.

Martín Alonso Gómez Zuleta, Universidad Nacional de Colombia

Profesor de medicina, Unidad de Gastroenterología, Universidad Nacional de Colombia. Hospital Universitario Nacional, Gastroenterólogo, Hospital de Kennedy, Bogotá.

Referencias bibliográficas

Arévalo A, Trespalacios AA, Otero W. Importancia de la proteína CagA en la infección por Helicobacter pylori. Rev. Col Gastroenterol 2009; 24 (4): 388-95.

Trespalacios AA, Otero W, Caminos J, et al. Phenotypic and Genotypic Analysis of Clarthromycin-Resistant Helicobacter pylori from Bogotá D.C., Colombia. J Microbiol. 2013; 51 (4): 448-452. doi: 10.1007/s12275-013-2465-6.

Otero W, Trespalacios AA, Otero E. Helicobacter pylori: Tratamiento actual. Un importante reto en gastroenterología. Rev Colomb Gastroenterol. 2009; 24(3):279-92.

Cammarota G, Sanguinetti M, Gallo A, Posteraro B. Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. Aliment Pharmacol Ther 2012; 36 (3): 222-230. doi: 10.1111/j.1365-2036.2012.05165.x.

Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology.

;153(2):420-429. doi: 10.1053/j.gastro.2017.04.022.

Cosme A, Montes M, Martos M, Gil I, Mendarte U, Salicio Y, et al. Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. Clinical Microbiology and Infection 2013;19(4):379-83. doi: 10.1111/j.1469-0691.2012.03844.x.

Peleteiro B, Bastos A, Ferro A, Nuno L. Prevalence of Helicobacter pylori Infection Worldwide: A Systematic Review of Studies with National Coverage. Dig Dis Sci 2014; 59 (8): 1698-1709. doi: 10.1007/s10620-014-3063-0.

Axon A. Helicobacter pylori and Public Health. Helicobacter 2014;19(Suppl 1): 68-73. doi: 10.1111/hel.12155.

Gisbert JP. Enfermedades relacionadas con la infección por Helicobacter pylori. Gastroenterol Hepatol. 2015;38(Supl 1):39-48. doi: 10.1016/S0210-5705(15)30018-2.

Gisbert JP. Enfermedades relacionadas con la infección por Helicobacter pylori. Gastroenterol Hepatol. 2014;37(Supl 3):40-52. doi: 10.1016/S0210-5705(14)70082-2.

Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311-5. doi: 10.1016/S0140-6736(84)91816-6.

Kyle R, Steensma D, Shampo M. Barry James Marshall-Discovery of Helicobacter pylori as a Cause of Peptic Ulcer. Mayo Clin Proc. 2016;91(5):e67-e68. doi: 10.1016/j.mayocp.2016.01.025.

Otero W, Gómez M, Trespalacios AA. Helicobacter pylori: después de todo. Temas escogidos de gastroenterología. Asociación Colombiana de Gastroenterología. 2007;43-56.

Urrego J, Otero W, Gomez M. Helicobacter prlori y enfermedades hematológicas. Rev Col Gastroenterol. 2013;28(4):329-37.

Mégraud F, Bessède E, Varon C, Helicobacter pylori infection and gastric carcinoma. Clin Microbiol Infect 2015;21(11):984-90. doi: 10.1016/j.cmi.2015.06.004.

Graham DY. Helicobacter pylori Update: Gastric Cancer, Reliable Therapy, and Possible Benefits. Gastroenterol 2015;148(4):719-31. doi: 10.1053/j.gastro.2015.01.040.

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241.

Gomez M, Ruiz O, Hernandez D, Albis R, Otero W, Sabbagh L. Erradicación del Helicobacter pylori: encuesta realizada por la Asociación Colombiana de Gastroenterología. Rev. Col Gastroenterol. 2015;30(1):25-31. doi: 10.22516/25007440.19.

Malfertheiner P, Venerito M, Selgrad M. Helicobacter pylori infection: selected aspects in clinical management. Curr Opin Gastroenterol. 2013;29(6):669-75. doi: 10.1097/MOG.0b013e328365d443.

Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67. doi: 10.1136/gutjnl-2015-309252.

Molina J, Shiotani A. Practical Aspects in Choosing a Helicobacter pylori Therapy. Gastroenterol Clin N Am 2015; 44:519–535. doi: 10.1016/j.gtc.2015.05.004.

Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-1153. doi: 10.1136/gut.2009.192757.

Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol. 2014;11(10):628–38. doi: 10.1038/nrgastro.2014.99.

Molina J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol. 2014;20(30):10338-47. doi: 10.3748/wjg.v20.i30.10338.

Sugimoto M, Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World J Gastroenterol. 2014;20(21):6400-11. doi: 10.3748/wjg.v20.i21.6400.

Furuta T, Graham DY. Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori Infection. Gastroenterol Clin N Am. 2010;39(3):465–80. doi: 10.1016/j.gtc.2010.08.007.

Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther. 2015;6(4):183-98. doi: 10.4292/wjgpt.v6.i4.183.

Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, et al. Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer. Ann Intern Med. 1998;129(12):1027-30. doi: 10.7326/0003-4819-129-12-199812150-00006.

Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLOS ONE. 2013;8(4):e62162. doi: 10.1371/journal.pone.0062162.

Lee JY, Kim N, Kim MS, Choi YJ, Lee JW, Yoon H, et al. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci. 2014;59:1235–43. doi: 10.1007/s10620-014-3093-7.

Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: Pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016;55:409–18. doi: 10.1007/s40262-015-0326-7.

Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335(1):231-8. doi: 10.1124/jpet.110.170274.

Sakurai Y, Nishimura A, Kennedy G, Hibberd M, Jenkins R, Okamoto H, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/ non-Japanese subjects. Clin Transl Gastroenterol 2015; 6:e94. doi: 10.1038/ctg.2015.18

Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015;75(4):439-43. doi: 10.1007/s40265-015-0368-z.

Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439-46. doi: 10.1136/gutjnl-2015-311304.

Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther.. 2017;46(2):106-14. doi: 10.1111/apt.14130.

Malfertheiner P, Selgrad M. Helicobacter pylori. Curr Opin Gastroenterol. 2014;30(6):589-95. doi: 10.1097/MOG.0000000000000128.

Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter.. 2017; 22(4). doi: 10.1111/hel.12392.

Camargo MC, García A, Riquelme A, et al. The Problem of Helicobacter pylori Resistance to Antibiotics: A Systematic Review in Latin America. Am J Gastroenterol. 2014;109(4):485-95. doi: 10.1038/ajg.2014.24.

Otero W, Otero L, Gómez M. Helicobacter pylori: tratamiento en 2018. En: Gómez M (editor). Temas Escogidos de Gastroenterología. 2018. p. 63-78.

Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514-33. doi: 10.1111/apt.13497.

Horiki N, Omata F, Uemura M, Suzuki S, Ishii N, Iizuka Y, et al. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter. 2009;14(5):86-90. doi: 10.1111/j.1523-5378.2009.00714.x.

Trespalacios AA, Otero W, Mercado M, et al. Impacto de la resistencia de Helicobacter pylori a los antimicrobianos en la eficacia de la terapia triple estándar y en dos triples terapias con levofloxacina en pacientes colombianos. Gastroenterol Latinoam. 2012;23:S35.

World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. WHO [internet] 2017 [acceso el 20 de diciembre de 2017]. Disponible en: www.who.int/entity/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/.

Wu JY, Liou JM, Graham DY. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol. 2014;8(1):21-8. doi: 10.1586/17474124.2014.859522.

Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift, Expert Review of Anti-infective Therapy 2016, 14(6):577-85. doi: 10.1080/14787210.2016.1178065.

Graham DY, Lee SY. How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly. Gastroenterol Clin North Am. 2015; 44: 537–563. doi: 10.1016/j.gtc.2015.05.003.

Trespalacios-Rangél AA, Otero W, Arévalo-Galvis A, Poutou-Piñales RA, Rimbara E, Graham DY. Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014). PLoS One. 2016;11(7):e0160007. doi: 10.1371/journal.pone.0160007.

Sugimoto M, Sahara S, Ichikawa H, Kagami T, Uotani T, Furuta T. High Helicobacter pylori cure rate with sitafloxacin-based triple therapy. Aliment Pharmacol Ther. 2015;42(4):477-83. doi: 10.1111/apt.13280.

Marcus EA, Sachs G, Scott DR. Eradication of Helicobacter pylori infection. Current gastroenterology reports. 2016;18(7):33. doi: 10.1007/s11894-016-0509-x.

Keogan DM, Griffith DM. Current and Potential Applications of Bismuth-Based Drugs. Molecules 2014; 19: 15258-97. doi: 10.3390/molecules190915258.

Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. doi: 10.1136/gutjnl-2016-312288.

Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut. 2012;61(5):646-64. doi: 10.1136/gutjnl-2012-302084.

Gisbert JP, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, et al. IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterol Hepatol. 2016;39(10):697-721. doi: 10.1016/j.gastrohep.2016.05.003.

Otero W, Trespalacios AA, Otero L, Vallejo M, Torres M, Pardo R, et al. Guía de práctica clínica para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos. Rev Col Gastroenterol. 2015;30(Suppl 1):17-33.

Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65(5):870-8. doi: 10.1136/gutjnl-2015-311019.

Zhang W, Chen Q, Lian X, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut. 2015;64:1715–20. doi: 10.1136/gutjnl-2015-309900.

Gokcan H, Oztas E, Onal IK. Different bismuth-based therapies for eradicating Helicobacter pylori: Randomized clinical trial of efficacy and safety. Clin Res Hepatol Gastroenterol. 2016;40:124-31. doi: 10.1016/j.clinre.2015.06.014.

O’Morain, C. and Montague, S. Challenges to Therapy in the Future. Helicobacter. 2000;5:23–6. doi: 10.1046/j.1523-5378.2000.0050S1023.x.

Perri F, Festa V, Andriulli A. Treatment of antibiotic-resistant Helicobacter pylori. N Engl J Med 1998; 339:53. doi: 10.1056/NEJM199807023390116.

Crabol Y, Catherinot E, Veziris N, et al. Rifabutin: where do we stand in 2016? J Antimicrob Chemother. 2016;71(7):1759-71. doi: 10.1093/jac/dkw024.

Della Bruna C, Schioppacassi G, Ungheri D, et al. LM 427, a new spiropiperidylrifamycin: in vitro and in vivo studies. J Antibiot (Tokyo). 1983;36:1502–6. doi: 10.7164/antibiotics.36.1502.

Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35:209–21. doi: 10.1111/j.1365-2036.2011.04937.x.

Graham DY, Lu H. Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread. Saudi J Gastroenterol. 2012; 18:1–2. doi: 10.4103/1319-3767.91724.

Cheng H, HU FL.Furazolidone , amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World J Gastroenterol. 2009;15:860-64. doi: 10.3748/wjg.15.860.

Lu H, Zhang W, Graham DY. Bismuth containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepato 2013;25:1134-40. doi: 10.1097/MEG.0b013e3283633b57.

Mohammadi M, Attaran B, Malekzadeh R, et al. Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran. Dig Dis Sci. 2017;62(8):1890-6. doi: 10.1007/s10620-017-4628-5.

Hu Y, Zhu Y, Lu N-H. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Front. Cell. Infect. Microbiol. 2017; 7:168. doi: 10.3389/fcimb.2017.00168.

Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;12:CD008337. doi: 10.1002/14651858.CD008337.pub2.

Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017;112:212-39. doi: 10.1038/ajg.2016.563.

Fallone C, Chiba N, van Zanten S, Fischbach L, Gisbert JP, Hunt R, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults, Gastroenterology 2016; 151, 51–69.e14. doi: 10.1053/j.gastro.2016.04.006.

Calvet X. Diagnosis of Helicobacter pylori Infection in the proton pump Inhibitor era. Gastroenterol Clin N Am. 2015;44(3):507-18. doi: 10.1016/j.gtc.2015.05.001.

Malfertheiner P, Mégraud F, O’Morain C, et al. Current European concepts in the management of Helicobacter pylori infection-the Maastricht Consensus Report. The European Helicobacter pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol. 1997;9:1-2. doi: 10.1097/00042737-199701000-00002.

Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12:177–186. doi: 10.1016/j.cgh.2013.05.028.

Hsu PI, Wu DC, Wu JH, et al. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011;16:139-45. doi: 10.1111/j.1523-5378.2011.00828.x.

Otero W, Gutiérrez O, Saabagh LC: Efectiveness of a hibrid therapy in eradicating Helicobacter pylori in a Colombian population. Gastroenterology. 2016;150:S246. doi: 10.1016/S0016-5085(16)30889-7.

Ducoumau A, Bénéjat L, Sifré LE, Lehours P, Mégraud F. Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods. Clin Microbiol Infect 2016;22:715-8. doi: 10.1016/j.cmi.2016.06.003.

Park CS, Lee SM, Park CH, et al. Pretreatment Antimicrobial Susceptibility-Guided Vs. Clarithromycin-Based Triple Therapy for Helicobacter pylori Eradication in a Region With High Rates of Multiple Drug Resistance. Am J Gastroenterol. 2014;109:1595-602. doi: 10.1038/ajg.2014.222.

Arévalo A, Trespalacios AA, Otero W. Personalized therapy for Helicobacter pylori: influence of cyp2c19 genotype in first triple therapy. Sometido y aceptado para publicación. Helicobacter. 2019.

Trespalacios-Rangél AA, Otero W, Arévalo-Galvis A, Poutou-Piñales RA, Rimbara E, Graham DY. Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014). PLoS One. 2016;11(7):e0160007. doi: 10.1371/journal.pone.0160007.

Villoria A, García P, Calvet X, Gisbert J, Vergara M. Meta-analysis: high dose proton pump inhibtor vs standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008;28:868-77. doi: 10.1016/S0016-5085(08)61572-3.

Segura AM, Gutiérrez O, Otero W, Angel LA, Genta R, Graham DY. Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1997;11:529-32. doi: 10.1046/j.1365-2036.1997.00172.x.

Otero W, Gutierrez O, Sierra F. Erradicación de H pylori con Terapia Triple: Bismuto, Furazolidona, Tetraciclina. Acta Med Col. 1996;21:218 (Res).

Some food additives, feed additives and naturally occurring substances. IARC Monogr Eval Carcinog Risk Chem Hum. 1983;31:1-291.

Auro A, Sumano H, Ocampo L, Barragán A. Evaluation the carcinogenic effects of furazolidone and its metabolites in two fish species. Pharmacogenomics J. 2004;4:24-8. doi: 10.1038/sj.tpj.6500216.

Sun Q, Liang X, Zheng Q. High efficacy of 14 –day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010;15:233-8. doi: 10.1111/j.1523-5378.2010.00758.x.

Ciccaglione AF, Tavani R, Grossi L, et al. Rifabutin containing triple therapy and rifabutin with bismuth Containing quadruple therapy for third-line treatment of Helicobacter pylori infection: Two pilot studies. Helicobacter. 2016;21:375–81. doi: 10.1111/hel.12296.

O’Connor A., Vaira D., Gisbert JP, O’Morain C. Treatment of Helicobacter pylori infection 2014. Helicobacter. 2014;19(Suppl 1):38–45. doi: 10.1111/hel.12163.

Szajewska H, Horvath A, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2015;41:1237–45. doi: 10.1111/apt.13214.

Luther J, Chey WD, Saad RJ. A clinician’s guide to salvage therapy for persistent Helicobacter pylori infection. Hosp Pract (1995). 2011;39:133-140. doi: 10.3810/hp.2011.02.383.

Yonezawa H, Osaki T, Kamiya S. Biofilm Formation by Helicobacter pylori and its involvement for antibiotic resistance. Biomed Res Int 2015;2015:914791. doi: 10.1155/2015/914791.

Cammarota G, Ianiro G, Bibbò S, et al. Culture-guided treatment approach for Helicobacter pylori infection: Review of the literature. World J Gastroenterol. 2014;20(18):5205-11. doi: 10.3748/wjg.v20.i18.5205.

Cammarota G, Branca G, Ardito F, et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol. 2010;8:817–20. doi: 10.1016/j.cgh.2010.05.006.

Graham DY, Calvet X. Guide Regarding Choice of Second-line Therapy to Obtain a High Cumulative Cure Rate. Helicobacter. 2012;17:243–5. doi: 10.1111/j.1523-5378.2012.00952.x.

Urrego JA, Otero W, Trespalacios A. Avances en la búsqueda de la vacuna contra Helicobacter pylori. MÉD.UIS. 2017;30(3):111-20.

Zeng M, Mao XH, Li JX, Tong WD, Wang B, Zhang YJ, et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(10002):1457-64. doi: 10.1016/S0140-6736(15)60310-5.

Sutton P. At last, vaccine-induced protection against Helicobacter pylori. Lancet. 2015;386(1002):1424-5. doi: 10.1016/S0140-6736(15)60579-7.

Descargas

Publicado

2018-12-30

Cómo citar

Morcillo-Muñoz, J. A., Regino-Otero, W. A., & Gómez Zuleta, M. A. (2018). Helicobacter pylori: ¿cómo mejorar las terapias de erradicación?. Revista Colombiana De Gastroenterología, 33(4), 437–447. https://doi.org/10.22516/25007440.314

Número

Sección

Revisión de tema

Métricas

Estadísticas de artículo
Vistas de resúmenes
Vistas de PDF
Descargas de PDF
Vistas de HTML
Otras vistas
QR Code

Algunos artículos similares: